ADC Therapeutics Reports Q1 Earnings and Provides Clinical Trial Update
ADC Therapeutics reported first-quarter net product revenue of $20 million for ZYNLONTA in Q1 2026, up from $17.4 million a year ago. The company expects top-line results from the Phase 3 LOTIS-5 trial by June and plans an sBLA submission if positive. ADC also reported reduced non-GAAP operating expenses to $42.9 million and ended Q1 with $231 million in cash.
Topics: biotech clinical_trials financial_performance pharmaceuticals